Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia

Mark S. Rouse, Melanie M. Hein, Paloma Anguita-Alonso, James M. Steckelberg, Robin Patel

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Ceftobiprole (BAL9141) is an investigational cephalosporin active against methicillin- and vancomycin-resistant staphylococci administered as a water-soluble prodrug, ceftobiprole medocaril (BAL5788). Using an immunocompetent murine pneumonia model of Haemophilus influenzae, Enterobacter cloacae, or extended-spectrum β-lactamase (ESBL) nonproducing or producing Klebsiella pneumoniae pneumonia, we compared results of treatment with ceftobiprole medocaril (71 mg/kg, sc, qid), ceftriaxone (50 mg/kg, im, bid), or cefepime (50 mg/kg, ip, q.i.d.). Results were expressed as median and 25th to 75th percentile log10 colony forming units per gram of lung tissue. Ceftobiprole, ceftriaxone, and cefepime were each more active than was no treatment and were equally active for treatment of experimental H. influenzae, E. cloacae, or ESBL-nonproducing K. pneumoniae pneumonia. For ESBL-producing K. pneumoniae, no differences were detected between no treatment and treatment with ceftobiprole, ceftriaxone, or cefepime. Ceftobiprole is active against H. influenzae, E. cloacae, and ESBL-nonproducing K. pneumoniae in an immunocompetent experimental murine pneumonia model.

Original languageEnglish (US)
Pages (from-to)333-336
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Volume55
Issue number4
DOIs
StatePublished - Aug 2006

Fingerprint

Enterobacter cloacae
Haemophilus influenzae
Klebsiella pneumoniae
Pneumonia
Ceftriaxone
Methicillin Resistance
Prodrugs
Cephalosporins
Vancomycin
Staphylococcus
Stem Cells
ceftobiprole
ceftobiprole medocaril
Lung
Water
cefepime

Keywords

  • Ceftobiprole medocaril
  • Enterobacter cloacae
  • Haemophilus influenzae
  • Klebsiella pneumoniae
  • Pneumonia

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Virology
  • Parasitology
  • Microbiology
  • Immunology
  • Applied Microbiology and Biotechnology

Cite this

Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. / Rouse, Mark S.; Hein, Melanie M.; Anguita-Alonso, Paloma; Steckelberg, James M.; Patel, Robin.

In: Diagnostic Microbiology and Infectious Disease, Vol. 55, No. 4, 08.2006, p. 333-336.

Research output: Contribution to journalArticle

@article{b64557d253864c099776c3ea2153c3a3,
title = "Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia",
abstract = "Ceftobiprole (BAL9141) is an investigational cephalosporin active against methicillin- and vancomycin-resistant staphylococci administered as a water-soluble prodrug, ceftobiprole medocaril (BAL5788). Using an immunocompetent murine pneumonia model of Haemophilus influenzae, Enterobacter cloacae, or extended-spectrum β-lactamase (ESBL) nonproducing or producing Klebsiella pneumoniae pneumonia, we compared results of treatment with ceftobiprole medocaril (71 mg/kg, sc, qid), ceftriaxone (50 mg/kg, im, bid), or cefepime (50 mg/kg, ip, q.i.d.). Results were expressed as median and 25th to 75th percentile log10 colony forming units per gram of lung tissue. Ceftobiprole, ceftriaxone, and cefepime were each more active than was no treatment and were equally active for treatment of experimental H. influenzae, E. cloacae, or ESBL-nonproducing K. pneumoniae pneumonia. For ESBL-producing K. pneumoniae, no differences were detected between no treatment and treatment with ceftobiprole, ceftriaxone, or cefepime. Ceftobiprole is active against H. influenzae, E. cloacae, and ESBL-nonproducing K. pneumoniae in an immunocompetent experimental murine pneumonia model.",
keywords = "Ceftobiprole medocaril, Enterobacter cloacae, Haemophilus influenzae, Klebsiella pneumoniae, Pneumonia",
author = "Rouse, {Mark S.} and Hein, {Melanie M.} and Paloma Anguita-Alonso and Steckelberg, {James M.} and Robin Patel",
year = "2006",
month = "8",
doi = "10.1016/j.diagmicrobio.2006.01.029",
language = "English (US)",
volume = "55",
pages = "333--336",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia

AU - Rouse, Mark S.

AU - Hein, Melanie M.

AU - Anguita-Alonso, Paloma

AU - Steckelberg, James M.

AU - Patel, Robin

PY - 2006/8

Y1 - 2006/8

N2 - Ceftobiprole (BAL9141) is an investigational cephalosporin active against methicillin- and vancomycin-resistant staphylococci administered as a water-soluble prodrug, ceftobiprole medocaril (BAL5788). Using an immunocompetent murine pneumonia model of Haemophilus influenzae, Enterobacter cloacae, or extended-spectrum β-lactamase (ESBL) nonproducing or producing Klebsiella pneumoniae pneumonia, we compared results of treatment with ceftobiprole medocaril (71 mg/kg, sc, qid), ceftriaxone (50 mg/kg, im, bid), or cefepime (50 mg/kg, ip, q.i.d.). Results were expressed as median and 25th to 75th percentile log10 colony forming units per gram of lung tissue. Ceftobiprole, ceftriaxone, and cefepime were each more active than was no treatment and were equally active for treatment of experimental H. influenzae, E. cloacae, or ESBL-nonproducing K. pneumoniae pneumonia. For ESBL-producing K. pneumoniae, no differences were detected between no treatment and treatment with ceftobiprole, ceftriaxone, or cefepime. Ceftobiprole is active against H. influenzae, E. cloacae, and ESBL-nonproducing K. pneumoniae in an immunocompetent experimental murine pneumonia model.

AB - Ceftobiprole (BAL9141) is an investigational cephalosporin active against methicillin- and vancomycin-resistant staphylococci administered as a water-soluble prodrug, ceftobiprole medocaril (BAL5788). Using an immunocompetent murine pneumonia model of Haemophilus influenzae, Enterobacter cloacae, or extended-spectrum β-lactamase (ESBL) nonproducing or producing Klebsiella pneumoniae pneumonia, we compared results of treatment with ceftobiprole medocaril (71 mg/kg, sc, qid), ceftriaxone (50 mg/kg, im, bid), or cefepime (50 mg/kg, ip, q.i.d.). Results were expressed as median and 25th to 75th percentile log10 colony forming units per gram of lung tissue. Ceftobiprole, ceftriaxone, and cefepime were each more active than was no treatment and were equally active for treatment of experimental H. influenzae, E. cloacae, or ESBL-nonproducing K. pneumoniae pneumonia. For ESBL-producing K. pneumoniae, no differences were detected between no treatment and treatment with ceftobiprole, ceftriaxone, or cefepime. Ceftobiprole is active against H. influenzae, E. cloacae, and ESBL-nonproducing K. pneumoniae in an immunocompetent experimental murine pneumonia model.

KW - Ceftobiprole medocaril

KW - Enterobacter cloacae

KW - Haemophilus influenzae

KW - Klebsiella pneumoniae

KW - Pneumonia

UR - http://www.scopus.com/inward/record.url?scp=33746440232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746440232&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2006.01.029

DO - 10.1016/j.diagmicrobio.2006.01.029

M3 - Article

C2 - 16631339

AN - SCOPUS:33746440232

VL - 55

SP - 333

EP - 336

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 4

ER -